<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795273</url>
  </required_header>
  <id_info>
    <org_study_id>TG005</org_study_id>
    <nct_id>NCT02795273</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Grass-SPIRE Registration Study</brief_title>
  <official_title>A Combined Phase 2b/3, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study to Assess the Efficacy and Safety of Grass-SPIRE in Subjects With Grass Pollen-Induced Allergic Rhinitis, With or Without Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of Grass-SPIRE compared with placebo and
      to evaluate the treatment effect of Grass-SPIRE on symptoms and use of rescue medication
      during the grass pollen season
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Decision made to stop study following availability of results from another study
  </why_stopped>
  <start_date>May 2016</start_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined Score of symptoms and allergy medication</measure>
    <time_frame>Approximately 66 weeks</time_frame>
    <description>Measurement of subject allergy symptoms (eg sneezing, watery eyes) and use of allergy medication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of Grass-SPIRE</measure>
    <time_frame>Approximately 66 weeks</time_frame>
    <description>Measurement of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom Scores</measure>
    <time_frame>Approximately 66 weeks</time_frame>
    <description>Categorical scores of allergy symptoms (eg sneezing, watery eyes) as assessed by subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Use</measure>
    <time_frame>Approximately 66 weeks</time_frame>
    <description>Use of allergy medication to help allergy symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Approximately 66 weeks</time_frame>
    <description>Assessment of Quality of Life measured by responses to a questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Rhinitis</condition>
  <condition>Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Grass-SPIRE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight intradermal injections of Grass-SPIRE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eight intradermal injections of Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grass-SPIRE</intervention_name>
    <arm_group_label>Grass-SPIRE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical history of grass pollen-induced allergic rhinitis with or without
             conjunctivitis for at least 2 years

          -  Score of ≤ 21 on RCAT questionnaire

          -  Rye grass specific IgE of ≥ 0.7 kU/L

          -  Positive skin prick test to Rye grass whole allergen extract

        Exclusion Criteria:

          -  History or findings of significant disease

          -  Asthma requiring GINA Step 3 or higher treatment

          -  History of severe drug allergy, severe angioedema or systemic allergic reaction

          -  Course of short-duration allergy-specific immunotherapy or more than 3 months
             treatment with long-duration allergen immunotherapy within 5 years

          -  Contraindications for administration of epinephrine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Bernstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernstein Clinical Research Center, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rhinitis</keyword>
  <keyword>Conjunctivitis</keyword>
  <keyword>Grass</keyword>
  <keyword>Allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

